GlassScriptPhysician profile
Kenneth M Rucker
NPI 1326088642
$3,129.36
in general payments reported to CMS, 2019-2025
21 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $221 · 2021: $175 · 2022: $321 · 2023: $593 · 2024: $525 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.03 | 2022-2025 | Qulipta, Vraylar, Creon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $661.70 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Amgen INC. | $284.95 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $204.44 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $185.34 | 2019-2022 | |
| Novo Nordisk INC | $172.19 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Janssen Pharmaceuticals, INC | $145.15 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.34 | 2019-2024 | Glassia |
| E.R. Squibb & Sons, L.L.C. | $97.47 | 2021-2024 | Eliquis |
| Lilly USA, LLC | $64.91 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $43.42 | 2019-2020 | |
| Exact Sciences Corporation | $32.25 | 2023-2024 | Cologuard Collection Kit |
| Medtronic Minimed, INC. | $28.30 | 2019 | |
| Celgene Corporation | $24.79 | 2019 | |
| Grifols USA, LLC | $23.50 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.41 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.90 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.18 | 2025 | Caplyta |
| Astellas Pharma US INC | $16.01 | 2019 | |
| Circassia INC. | $14.43 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Rucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.